Search research articles
Contact Us
Filters
Showing results (31-40 of 44) with videos related to
Page
of 5
Sort By:
Chest
|
December 1, 1994
p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871
D P Carbone, T Mitsudomi, I Chiba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2001
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer
G Konecny, M Untch, J Arboleda, et al.
Current Medical Research and Opinion
|
February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
T Bell, J P Crown, I Lang, et al.
Blood
|
November 15, 1989
Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors
D W Anderson, J S Epstein, T H Lee, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
June 2, 2009
In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers
H C Swaisland, S D Oliver, T Morris, et al.
Biochemical Pharmacology
|
February 13, 2001
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase
D B Lackey, M P Groziak, M Sergeeva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2023
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
F André, F Su, N Solovieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 23, 2024
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
F André, N Solovieff, F Su, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
G Curigliano, V Mueller, V Borges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2022
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]
G Curigliano, V Mueller, V Borges, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 44) with videos related to
Sort By:
Page
of 5
Chest
|
December 1, 1994
p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871
D P Carbone, T Mitsudomi, I Chiba, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 8, 2001
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer
G Konecny, M Untch, J Arboleda, et al.
Current Medical Research and Opinion
|
February 20, 2016
Impact of palbociclib plus letrozole on pain severity and pain interference with daily activities in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer as first-line treatment
T Bell, J P Crown, I Lang, et al.
Blood
|
November 15, 1989
Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors
D W Anderson, J S Epstein, T H Lee, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems
|
June 2, 2009
In vitro metabolism of the specific endothelin-A receptor antagonist ZD4054 and clinical drug interactions between ZD4054 and rifampicin or itraconazole in healthy male volunteers
H C Swaisland, S D Oliver, T Morris, et al.
Biochemical Pharmacology
|
February 13, 2001
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase
D B Lackey, M P Groziak, M Sergeeva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 6, 2023
Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials
F André, F Su, N Solovieff, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 23, 2024
Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials
F André, N Solovieff, F Su, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 26, 2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
G Curigliano, V Mueller, V Borges, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 23, 2022
Corrigendum to "Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2D metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis": [Annals of Oncology 33 (2022) 321-329]
G Curigliano, V Mueller, V Borges, et al.
Page
of 5